Cooper Online Buprenorphine Training

Cooper’s Department of Addiction Medicine invites attending physicians, advanced practitioners, residents, fellows, and medical students to become part of the growing community of health care providers working to address the opioid epidemic and heal their communities.

On Wednesday, May 20, 2020, from 5 p.m. to 9 p.m., Addiction Medicine will offer a live WebEx training on medication-assisted treatment (MAT)/buprenorphine waivers.

Once you have completed the WebEx training, you will have the option to participate in an additional, free online training session to become eligible for your DEA X-waiver, which will allow you to prescribe buprenorphine. To participate in the second training course, please contact Addiction Medicine faculty members Kaitlan Baston, MD; Ryan Schmidt, MD; or Christopher Milburn, MD, for additional information. Mentoring opportunities about how to integrate the training into your practice are also available.

To register for the WebEx training on May 20, 2020, please email pileggi@rowan.edu. Provide your name, department, and location; in the subject line, please be sure to include “Buprenorphine Training RSVP.”

The Cooper Health System is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Cooper Health System takes responsibility for the content, quality, and scientific integrity of this CME activity.

This Training is sponsored by SAMHSA and PCSS. PCSS designates this activity for a maximum of 4.0 AMA PRA Category 1 CreditsTM once the online portion is complete.  Providers should claim only the credit commensurate with the extent of their participation in the activity.

Funding for this training was made possible in part by grant-5H79TI081667-02 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.